In vivo glycation-interplay between oxidant and carbonyl stress in bone.

aging and diabetes bone extracellular matrix proteins glycation glycoxidation metabolic syndromes oxidant and carbonyl stress

Journal

JBMR plus
ISSN: 2473-4039
Titre abrégé: JBMR Plus
Pays: England
ID NLM: 101707013

Informations de publication

Date de publication:
Nov 2024
Historique:
received: 09 08 2023
revised: 18 06 2024
accepted: 28 07 2024
pmc-release: 08 08 2025
medline: 10 10 2024
pubmed: 10 10 2024
entrez: 10 10 2024
Statut: epublish

Résumé

Metabolic syndromes (eg, obesity, type 2 diabetes (T2D), atherosclerosis, and neurodegenerative diseases) and aging, they all have a strong component of carbonyl and reductive-oxidative (redox) stress. Reactive carbonyl (RCS) and oxidant (ROS) stress species are commonly generated as products or byproducts of cellular metabolism or are derived from the environment. RCS and ROS can play a dual role in living organisms. Some RCS and ROS function as signaling molecules, which control cellular defenses against biological and environmental assaults. However, due to their high reactivity, RCS and ROS inadvertently interact with different cellular and extracellular components, which can lead to the formation of undesired posttranslational modifications of bone matrix proteins. These are advanced glycation (AGEs) and glycoxidation (AGOEs) end products generated in vivo by non-enzymatic amino-carbonyl reactions. In this review, metabolic processes involved in generation of AGEs and AGOEs within and on protein surfaces including extracellular bone matrix are discussed from the perspective of cellular metabolism and biochemistry of certain metabolic syndromes. The impact of AGEs and AGOEs on some characteristics of mineral is also discussed. Different therapeutic approaches with the potential to prevent the formation of RCS, ROS, and the resulting formation of AGEs and AGOEs driven by these chemicals are also briefly reviewed. These are antioxidants, scavenging agents of reactive species, and newly emerging technologies for the development of synthetic detoxifying systems. Further research in the area of in vivo glycation and glycoxidation should lead to the development of diverse new strategies for halting the progression of metabolic complications before irreversible damage to body tissues materializes.

Identifiants

pubmed: 39386996
doi: 10.1093/jbmrpl/ziae110
pii: ziae110
pmc: PMC11458925
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

ziae110

Informations de copyright

Published by Oxford University Press on behalf of the American Society for Bone and Mineral Research 2024.

Déclaration de conflit d'intérêts

The authors have no conflict of interest to declare.

Auteurs

Grażyna E Sroga (GE)

Department of Biomedical Engineering, Rensselaer Polytechnic Institute, Troy, NY, United States.
Shirley Ann Jackson PhD Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, United States.

Deepak Vashishth (D)

Department of Biomedical Engineering, Rensselaer Polytechnic Institute, Troy, NY, United States.
Shirley Ann Jackson PhD Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, United States.
Center for Engineering and Precision Medicine, Rensselaer-Icahn School of Medicine at Mount Sinai, 619 West 54th Street, New York, NY 10019, United States.

Classifications MeSH